Date | Price Target | Rating | Analyst |
---|---|---|---|
8/6/2024 | $27.00 → $19.00 | Buy | Needham |
3/28/2024 | $25.00 | Overweight | Piper Sandler |
10/12/2022 | $20.00 | Buy | Jefferies |
4/7/2022 | $34.00 | Overweight | Cantor Fitzgerald |
3/1/2022 | $30.00 → $28.00 | Overweight | Morgan Stanley |
1/18/2022 | $43.00 → $36.00 | Buy | B of A Securities |
12/21/2021 | $35.00 → $30.00 | Buy | Truist Securities |
11/9/2021 | $42.00 → $36.00 | Market Outperform | JMP Securities |
SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/r-x6CjRnDNsnPR3wF7sxumTszz?domain=cc.webcasts.com. Live audio of the webcast will be available on the "Investors" section of the company's w
SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroiliac joint fusion. TNT includes a porous threaded implant with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and into the contralateral ilium (through
SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/1f7GCNk84yt0E1qNsm3zxj?domain=wsw.com. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The
SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/r-x6CjRnDNsnPR3wF7sxumTszz?domain=cc.webcasts.com. Live audio of the webcast will be available on the "Investors" section of the company's w
SANTA CLARA, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will be participating in the upcoming 2024 Canaccord Genuity 44th Annual Growth Conference in Boston. Management will be hosting a fireside chat on Wednesday, August 14th, 2024, at 3:30 p.m. Eastern Time/ 1:30 p.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/1f7GCNk84yt0E1qNsm3zxj?domain=wsw.com. Live audio of the webcast will be available on the "Investors" section of the company's website at: www.si-bone.com. The
Increases 2024 revenue guidance to $165 million - $167 millionExpects to achieve positive Adjusted EBITDA in Fourth Quarter 2024 SANTA CLARA, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (NASDAQ:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (comparisons are to the prior year period) Worldwide revenue of $40.0 million, representing growth of ~20% U.S. revenue of $37.8 million, representing growth of ~21%Gross margin of ~79%Net loss of $8.9 million, representing an improvement of ~20%Adjusted EBITDA loss of $2.7 million, representing an i
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
SC 13G - SI-BONE, Inc. (0001459839) (Subject)
SC 13G/A - SI-BONE, Inc. (0001459839) (Subject)
Needham reiterated coverage of SI-BONE with a rating of Buy and set a new price target of $19.00 from $27.00 previously
Piper Sandler initiated coverage of SI-BONE with a rating of Overweight and set a new price target of $25.00
Jefferies initiated coverage of SI-BONE with a rating of Buy and set a new price target of $20.00
Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company's board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay's total board membership to seven. "We are pleased to welcome these two transformational business leaders as new independent directors on the Board," said David Brabazon, Chairman of the Mainstay Board of Directors. "Their deep experience will be invaluable to Mainstay as we grow our business and pursue our mission to serve patients with intractable chronic low back pain." "As our business evolves and we continue to focus on commercial growth, broadening the industry expertise on our Board will help
SANTA CLARA, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the appointment of Anshul Maheshwari as the company's Chief Financial Officer effective April 20, 2021, and the addition of Helen Loh and Laura Francis to its Board of Directors effective April 18, 2021. The appointment of Mr. Maheshwari completes the recently announced senior leadership transition which includes Laura Francis succeeding Jeff Dunn as Chief Executive Officer, and Tony Recupero becoming President, Commercial Operations. Jeff Dunn will remain with the compa
Laura Francis to Become Chief Executive Officer; Jeff Dunn to Become Executive Chairman; and Tony Recupero to Become President. SANTA CLARA, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN) (“SI-BONE” or the “Company”), a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, today announced its intention to appoint Laura Francis as Chief Executive Officer and to the board of directors. Laura Francis currently serves as SI-BONE’s Chief Financial Officer and Chief Operating Officer. As CEO, Laura Francis will succeed Jeff Dunn, who will remain with the Company as Execut
Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $25 to $21.
Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $26 to $25.
JMP Securities analyst David Turkaly reiterates SI-BONE (NASDAQ:SIBN) with a Market Outperform and maintains $32 price target.
144 - SI-BONE, Inc. (0001459839) (Subject)
10-Q - SI-BONE, Inc. (0001459839) (Filer)
8-K - SI-BONE, Inc. (0001459839) (Filer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)
4 - SI-BONE, Inc. (0001459839) (Issuer)